XML 31 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
Mar. 31, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 98,770,907 $ 33,719,796
Short-term investments 18,011,492 18,905,608
Accounts receivable 2,699,570 3,301,563
Accounts receivable from affiliated entity 18,652 0
Prepaid expenses and other current assets 464,093 637,433
Prepaid expenses and other current assets from affiliated entity 1,657,734 2,057,350
Deferred tax asset 61,839 61,839
Total current assets 121,684,287 58,683,589
Restricted cash 100,849 100,762
Fixed assets, net 3,021,222 2,886,545
Investment in affiliated entity 9,287,624 9,664,587
Intangible assets, net 5,478,966 5,718,778
Goodwill 10,113,371 [1] 10,113,371 [1]
Common stock warrants 1,410,000 717,500
Other assets 561,326 402,075
Total assets 151,657,645 88,287,207
Current liabilities:    
Accounts payable and accrued expenses 5,250,417 5,444,508
Accounts payable and accrued expenses due to affiliated entity 779,500 522,255
Accrued clinical trial expenses 1,735,148 1,446,180
Common stock warrants 6,045,903 19,540,583
Deferred revenue 1,454,065 1,624,388
Deferred revenue from affiliated entity 376,041 388,542
Total current liabilities 15,641,074 28,966,456
Deferred revenue, net of current portion 2,315,158 1,997,333
Deferred revenue from affiliated entity, net of current portion 1,117,944 1,211,694
Deferred rent 3,207,784 3,013,263
Deferred tax liabilities 195,778 195,778
Total liabilities 22,477,738 35,384,524
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 240,147 210,305
Additional paid-in capital 435,183,356 348,109,661
Accumulated deficit (306,610,037) (295,788,577)
Accumulated other comprehensive loss (71,810) (76,365)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 128,741,656 52,455,024
Non-controlling interest 438,251 447,659
Total stockholders’ equity 129,179,907 52,902,683
Total liabilities and stockholders’ equity $ 151,657,645 $ 88,287,207
[1] Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.